Janet Kidd StewartVerified
As seen in: Freelance, Los Angeles Times, Chicago Tribune, Seattle Times, Newsday, Miami Herald, The Sacramento Bee, The Mercury News and 56 more, The Columbus Dispatch, Star Tribune, Buffalo News, Spokesman-Review, News & Observer, Kansas City Star, Philly.com, Daily News, St. Louis Post-Dispatch, The Modesto Bee, The Record (Bergen County), Austin American-Statesman, Pioneer Press, The Charlotte Observer, Omaha World-Herald, Tacoma News Tribune, Wichita Eagle, Albany Times Union, Sun Herald, San Luis Obispo Tribune, Albuquerque Journal, Rock Hill Herald, The Monterey County Herald, The National Memo, The State, Bradenton Herald, Idaho Statesman, The Reporter (Vacaville, CA), The Ledger, Post-Bulletin, Belleville News-Democrat, Daily Democrat, Centre Daily Times, Medical Economics, Herald & Review, Modern Medicine, The Daily News (Palo Alto), Lexington Herald-Leader, The Telegraph (Macon), Vallejo Times-Herald, Merced Sun-Star, Watertown Daily Times (Watertown, NY), Columbus Ledger-Enquirer, The Island Packet, Keene Sentinel, The Bellingham Herald, The Sun News, The Olympian, Physicians Practice, Cary News, Barrington Courier-Review, Herald News, Fort Lee Suburbanite, East Bay Times, Ahora Si!, Prostate Cancer News Today
Is this you? Contact us to edit this page
Are You a Journalist?
Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.Create a Portfolio
Metastatic Prostate Cancer Therapy Zytiga Focus of Janssen's Filing of FDA Supplemental New Drug Application
prostatecancernewstoday.com — Janssen Biotech seeks U.S. approval to use a triple combination treatment with Zytiga (abiraterone acetate), prednisone and androgen deprivation therapy (ADT) for men with high-risk metastatic hormone naïve prostate cancer (HNPC) or newly diagnosed, high-risk metastatic hormone sensitive prostate cancer (HSPC). As such, the Danish pharmaceutical giant submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for that purpose.
newsobserver.com — Americans often feel better about their 401(k) balances than they should, and that's particularly true today, a new survey shows. A new breed of financial pros aims to better align client perceptions with reality. Almost half of the survey respondents (47 percent) said they feel somewhat or much more secure financially than they did five years ago, not surprising given the strong financial market performance in recent years.
Also in: thestate.com, bradenton.com, myrtlebeachonline.com, macon.com, theolympian.com, bellinghamherald.com, mercedsunstar.com, ledger-enquirer.com, heraldonline.com
prostatecancernewstoday.com — Men who began taking statins after being diagnosed with prostate cancer were less like to die than men not on statins, found a Danish study that urged more research to establish whether statins have a real potential to treat the disease. The study, “Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer,” appeared in the Journal of Clinical Oncology.